June 3, 2024 2:52 PM
GSK blood cancer drug nearly halves risk of death in late-stage trial
GSK's GSK.L multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunda...